Neoleukin Therapeutics Investor Relations Material

Neoleukin Therapeutics (NCT), a biopharmaceutical company developing immunotherapies for cancer, inflammation and autoimmunity diseases using protein design technology. NCT's lead product candidate is an immunotherapy for non-small cell lung cancer (NSCLC) which relies on novel combination of biologic agents to fight cancer. The company develops protein-based therapies that direct the body's immune system to attack diseased cells. It is developing TLR4 agonists for treatment of inflammatory diseases and cancer, notably Phase III-ready NP1201TLR4.